Market size, growth to 2033 and clinical trials, side by side.
China is the bigger Diabetes Management market: $6.3 Bn against $1.4 Bn in 2023, about 4.4 times as large.
India grows faster: 10.1% a year, against 8.6%. The gap still grows from $4.9 Bn to $10.6 Bn by 2033.
Clinical research: 399 active trials in China, 51 in India.
| Measure | ||
|---|---|---|
| Market size, 2023 | $6.3 Bn | $1.4 Bn |
| Market size, 2033 projected | $14.3 Bn | $3.7 Bn |
| Growth a year (CAGR) | 8.6% | 10.1% |
| Money added, 2023–2033 | $8 Bn | $2.3 Bn |
| Share of the world market | 8% | 1.8% |
| Size rank of 24 countries | #2 | #12 |
| Market per person, 2023 | $4.46 | $0.97 |
| Active clinical trials | 399 | 51 |
| Diabetes (adults) % of adults (WHO) | 11.2 2022 | 22.6 2022 |
| Full report | China report | India report |
China India · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
China is the bigger Diabetes Management market: $6.3 Bn against $1.4 Bn in 2023, about 4.4 times as large.
India grows faster: 10.1% a year, against 8.6%. The gap still grows from $4.9 Bn to $10.6 Bn by 2033.
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Health figures: WHO. Population: World Bank.